GlycoT Therapeutics aims to apply its innovative and proprietary chemoenzymatic glycosylation technology for glycoengineering of therapeutic proteins such as monoclonal antibodies to improve their therapeutic efficacy. In addition, the company also applies its technology for producing enzymes, oligosaccharides, glycopeptides, and other glycoprotein products as valuable research tools for disease diagnosis and glycobiology research field